© Reuters. Moderna Therapeutics seen during COVID-19 in Massachusetts
(Reuters) – Modern Inc (O :), one of the pioneers in the race to develop a vaccine for the novel coronavirus, said on Thursday it was preparing to launch the experimental vaccine and had already received $ 1.1 billion in deposits for supply.
The Cambridge, Massachusetts-based company has signed agreements with the US government and several other countries, and is in talks with a WHO-led group for the supply of the vaccine, which is being tested in humans. at an advanced stage.
While the company did not give a clear timeline for releasing data from those trials on Thursday, it said the first data is expected in the coming weeks, based on the number of infections seen in its study of 30,000. volunteers.
Moderna, which does not yet have any approved products on the market, is one of the few companies in the final testing phase for the vaccine, with major drugmakers like Johnson & Johnson (N 🙂 and Pfizer Inc (N :).
“I think that if we launch our COVID-19 vaccine, 2021 could be the most important inflection year in Moderna’s history,” said CEO Stéphane Bancel.
The company said it was in talks with the World Health Organization-backed COVAX facility over a tiered price proposal for its vaccine.
Fusion Media or anyone involved with Fusion Media will not accept any responsibility for loss or damage resulting from reliance on any information, including data, quotes, graphics, and buy / sell signals contained in this website. Be fully informed of the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.